Yinkun Liu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Yinkun Liu has a total of 269 co-authors. Here are the top co-authors by number of shared publications:
Kun Guo
Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion, Fudan University, Ministry of Education, Shanghai 200032, P.R. China
21 shared publicationsLu Sun
Cancer Research Center, Institute of Biomedical Science, Fudan University, Shanghai 200032, China
17 shared publications- Xiao-Nan Kang
Renji Biobank, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
17 shared publications Shu Zhang
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China; Cancer Research Center, Institute of Biomedical Science, Fudan University, Shanghai 200032, China
15 shared publicationsXiaonan Kang
Cancer Research Center, Institute of Biomedical Science, Fudan University, Shanghai, People's Republic of China
13 shared publicationsYan Li
Liver Cancer Institute, Zhongshan Hospital, Fudan University, Shanghai 200032, China
13 shared publications
Latest Publications
- Open Access
- 21 May 2018
- Published by Smart Science and Technology, LLC in Precision Medicine
- Vol. 3
Glycobiomarkers for precise diagnosis of liver diseases
Glycobiomarkers are valuable for disease diagnostics, monitoring and prognostics with greater sensitivity and specificity than the currently used biomarkers. For liver diseases diagnostics, Wisteria floribunda agglutinin (WFA)-positive human Mac-2-binding protein, fucosylated haptoglobin, vitronectin, antithrombin III, WFA-positive colony stimulating factor 1 receptor and fucosylated hemopexin were recently reported to be promising glycobiomarkers, including fucosylated serum paraoxonase 1 and fucosylated GP73 in our previous studies. Large-scale validation and clinical trials of most glycobiomarkers are urgently needed for crossing the boundary from the laboratory into routine clinical use.
- 21 May 2018
- Published by Smart Science and Technology, LLC in Precision Medicine
- Vol. 3
Open AccessGlycobiomarkers for precise diagnosis of liver diseases
Glycobiomarkers are valuable for disease diagnostics, monitoring and prognostics with greater sensitivity and specificity than the currently used biomarkers. For liver diseases diagnostics, Wisteria floribunda agglutinin (WFA)-positive human Mac-2-binding protein, fucosylated haptoglobin, vitronectin, antithrombin III, WFA-positive colony stimulating factor 1 receptor and fucosylated hemopexin were recently reported to be promising glycobiomarkers, including fucosylated serum paraoxonase 1 and fucosylated GP73 in our previous studies. Large-scale validation and clinical trials of most glycobiomarkers are urgently needed for crossing the boundary from the laboratory into routine clinical use.
- 6 October 2017
- Published by Taylor & Francis in Future Oncology
- Vol. 13 (23) , 2053-2063
S100A6 promotes proliferation of intrahepatic cholangiocarcinoma cells via the activation of the p38/MAPK pathway
Aim: We explored the expression of S100A6 and its role in intrahepatic cholangiocarcinoma (ICC). Methods: The expression of S100A6 in ICC samples was detected by immunohistochemistry. In vitro experiments, we silenced and overexpressed S100A6 to investigate its role in cell functions. Results: The expression of S100A6 was markedly increased in ICC tissues and cell lines. S100A6 overexpression was an independent risk factor for patients’ survival. Silencing S100A6 resulted in a suppression of proliferation and p38/MAPK activity, while overexpressing S100A6 caused a promotion of proliferation and p38/MAPK. Discussion: S100A6 participated in the proliferation of ICC cells and correlated with a more aggressive behavior of ICC. Conclusion: S100A6 may serve as a novel prognostic marker and a potential therapeutic target for ICC patients.
- 6 October 2017
- Published by Taylor & Francis in Future Oncology
- Vol. 13 (23) , 2053-2063
S100A6 promotes proliferation of intrahepatic cholangiocarcinoma cells via the activation of the p38/MAPK pathway
Aim: We explored the expression of S100A6 and its role in intrahepatic cholangiocarcinoma (ICC). Methods: The expression of S100A6 in ICC samples was detected by immunohistochemistry. In vitro experiments, we silenced and overexpressed S100A6 to investigate its role in cell functions. Results: The expression of S100A6 was markedly increased in ICC tissues and cell lines. S100A6 overexpression was an independent risk factor for patients’ survival. Silencing S100A6 resulted in a suppression of proliferation and p38/MAPK activity, while overexpressing S100A6 caused a promotion of proliferation and p38/MAPK. Discussion: S100A6 participated in the proliferation of ICC cells and correlated with a more aggressive behavior of ICC. Conclusion: S100A6 may serve as a novel prognostic marker and a potential therapeutic target for ICC patients.
- Open Access
- 28 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (37) , 62011-62028
Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics
Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics
- 28 June 2017
- Published by Impact Journals, LLC in Oncotarget
- Vol. 8 (37) , 62011-62028
Open AccessIdentification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics
Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics Identification of CD14 as a potential biomarker of hepatocellular carcinoma using iTRAQ quantitative proteomics
- Open Access
- 28 February 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 13 (4) , 2599-2606
Oct4 induces EMT through LEF1/β-catenin dependent WNT signaling pathway in hepatocellular carcinoma
Octamer 4 (Oct4), a member of the Pit-Oct-Unc transcription factor family required to maintain self-renewal and pluripotency of embryonic stem cells, has been previously identified to be associated with tumorigenesis and malignant transformation of numerous types of cancer including hepatocellular carcinoma (HCC). The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line. To increase understanding of the role of Oct4 in HCC, the present study used a functional genomics approach and analyzed the resulting transcriptional profiles to identify Oct4-dependent genes in Huh7. Affymetrix GeneChip Human genome U133 Plus 2.0 Arrays were used to determine differential gene expression profiles and then validated by quantitative polymerase chain reaction. The present study found that altered expression of 673 genes (fold-change ≥2) affected multiple signaling pathways linked with self-renew and metastasis. Among these differentially expressed genes, the present study noticed that the key component of the WNT signaling pathway lymphoid enhancer binding factor 1 (LEF1) and Twist Family BHLH transcription factor 1 were upregulated by Oct4, whilst cadherin 2 was downregulated. Additional studies found that the nuclear β-catenin aggregation was increased in Oct4 overexpressed HCC cell lines. These results suggest that Oct4 regulates LEF1 to active LEF1/β-catenin dependent WNT signaling pathway and promote epithelial-mesenchymal transition. The present findings provide novel mechanistic insight into an important role of Oct4 in HCC.
- 28 February 2017
- Published by Spandidos Publications in Oncology Letters
- Vol. 13 (4) , 2599-2606
Open AccessOct4 induces EMT through LEF1/β-catenin dependent WNT signaling pathway in hepatocellular carcinoma
Octamer 4 (Oct4), a member of the Pit-Oct-Unc transcription factor family required to maintain self-renewal and pluripotency of embryonic stem cells, has been previously identified to be associated with tumorigenesis and malignant transformation of numerous types of cancer including hepatocellular carcinoma (HCC). The present data shows that Oct4 enhances cancer stem cell properties and increases invasion ability in the Huh7 cell line. To increase understanding of the role of Oct4 in HCC, the present study used a functional genomics approach and analyzed the resulting transcriptional profiles to identify Oct4-dependent genes in Huh7. Affymetrix GeneChip Human genome U133 Plus 2.0 Arrays were used to determine differential gene expression profiles and then validated by quantitative polymerase chain reaction. The present study found that altered expression of 673 genes (fold-change ≥2) affected multiple signaling pathways linked with self-renew and metastasis. Among these differentially expressed genes, the present study noticed that the key component of the WNT signaling pathway lymphoid enhancer binding factor 1 (LEF1) and Twist Family BHLH transcription factor 1 were upregulated by Oct4, whilst cadherin 2 was downregulated. Additional studies found that the nuclear β-catenin aggregation was increased in Oct4 overexpressed HCC cell lines. These results suggest that Oct4 regulates LEF1 to active LEF1/β-catenin dependent WNT signaling pathway and promote epithelial-mesenchymal transition. The present findings provide novel mechanistic insight into an important role of Oct4 in HCC.
- 15 December 2016
- Published by Springer Nature
- p. 59-91
Screening and Identification of Molecular Marker for Metastatic Liver Cancer
- 15 December 2016
- Published by Springer Nature
- p. 59-91
Screening and Identification of Molecular Marker for Metastatic Liver Cancer
- 18 October 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 12 (6) , 4744-4748
A novel anti-adhesion peptide (β3) inhibits hepatocellular carcinoma activity in vitro and in vivo
The present study aimed to investigate the blocking of tumor cell adhesion to the extracellular matrix, the prevention of tumor metastasis by the β peptide trimer β3, as well as the influence of β3 on the recurrence and survival time of hepatocellular carcinoma (HCC) nude mice model LCI-D20 after early resection. To this end, the DNA fragment of the β3 peptide (DLYYLMDLSYSMKGGDLYYLMDLSYSMKGGDLYYLMDLSYSMK) was cloned into the expression vector pET-His and the fusion protein His-β3 was expressed in E. coli BL21 (DE3) plysS. The anti-adhesion effect of β3 on the highly metastatic HCC cell line HCCLM6 to fibronectin (FN) was measured by MTT assay. The inhibition of HCCLM6 cell invasion by β3 was analyzed using a Transwell (modified Boyden chamber) system and Matrigel. The influence of β3 on the recurrence of HCC and mouse survival time after early resection was investigated using the HCC metastasis nude mice model LCI-D20. HCCLM6 cells incubated with 10, 20, 50 or 100 µmol/l β3 for 3 h demonstrated a marked reduction in adhesion to FN. The adhesion inhibition rates were 11.8, 21.7, 37.5 and 66.4%, respectively. In addition, cell invasion was reduced by 51.3% in HCCLM6 cells cultured with 100 µmol/l β3. Treatment with β3 also inhibited tumor recurrence at the incisal edge and prolonged the survival time of LCI-D20 mice following early resection. The present study provided evidence that β3 peptide specifically blocked the adhesion and invasion of HCCLM6 cells, inhibited HCC recurrence in vivo and prolonged the survival time of HCC nude mice LCI-D20 following hepatectomy. Therefore, β3 may be further investigated as a novel anti-tumor drug.
- 18 October 2016
- Published by Spandidos Publications in Oncology Letters
- Vol. 12 (6) , 4744-4748
A novel anti-adhesion peptide (β3) inhibits hepatocellular carcinoma activity in vitro and in vivo
The present study aimed to investigate the blocking of tumor cell adhesion to the extracellular matrix, the prevention of tumor metastasis by the β peptide trimer β3, as well as the influence of β3 on the recurrence and survival time of hepatocellular carcinoma (HCC) nude mice model LCI-D20 after early resection. To this end, the DNA fragment of the β3 peptide (DLYYLMDLSYSMKGGDLYYLMDLSYSMKGGDLYYLMDLSYSMK) was cloned into the expression vector pET-His and the fusion protein His-β3 was expressed in E. coli BL21 (DE3) plysS. The anti-adhesion effect of β3 on the highly metastatic HCC cell line HCCLM6 to fibronectin (FN) was measured by MTT assay. The inhibition of HCCLM6 cell invasion by β3 was analyzed using a Transwell (modified Boyden chamber) system and Matrigel. The influence of β3 on the recurrence of HCC and mouse survival time after early resection was investigated using the HCC metastasis nude mice model LCI-D20. HCCLM6 cells incubated with 10, 20, 50 or 100 µmol/l β3 for 3 h demonstrated a marked reduction in adhesion to FN. The adhesion inhibition rates were 11.8, 21.7, 37.5 and 66.4%, respectively. In addition, cell invasion was reduced by 51.3% in HCCLM6 cells cultured with 100 µmol/l β3. Treatment with β3 also inhibited tumor recurrence at the incisal edge and prolonged the survival time of LCI-D20 mice following early resection. The present study provided evidence that β3 peptide specifically blocked the adhesion and invasion of HCCLM6 cells, inhibited HCC recurrence in vivo and prolonged the survival time of HCC nude mice LCI-D20 following hepatectomy. Therefore, β3 may be further investigated as a novel anti-tumor drug.
- Open Access
- 9 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (42) , 68242-68252
Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
- 9 September 2016
- Published by Impact Journals, LLC in Oncotarget
- Vol. 7 (42) , 68242-68252
Open AccessQuantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma Quantitative proteomics reveals FLNC as a potential progression marker for the development of hepatocellular carcinoma
- Open Access
- 27 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24558
Type conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC
Macrophages play important roles in the tumor microenvironment, driving cancer progression and metastasis, particularly in hepatocellular carcinoma (HCC). However, few studies have assessed the exact secretome composition in HCC. In the present study, the impact of different phenotype of macrophages on HCC cells was investigated. Alternatively activated macrophages (M2) were found to significantly increase the proliferation, migration and invasion abilities of SMMC7721 cells (all P < 0.05). M2 were then co-cultured with SMMC7721 cells to reconstruct the tumor microenvironment. Conditioned medium from 3D single cultures of M2, SMMC7721 cells and their co-culture system were analyzed using quantitative proteomics via iTRAQ labeling combined with mass spectrometric analysis. Secretome analysis revealed a total of 159 differential secreted proteins in the co-culture system compared to the single culture systems, with 63 being up-regulated (>1.3-fold) and 96 down-regulated (<0.7-fold). CXCL2 was confirmed to have higher expression in the co-culture system and HCC tissues and was selected for further investigation. Functional effects data suggested that recombinant human CXCL2 significantly enhanced the migration, invasion ability of SMMC7721 cells and weakened adhesion ability. While CXCL2 neutralization and CXCR2 blockage significantly inhibited the effects of CXCL2 on SMMC7721 cells, indicating that CXCL2 may play pivotal role in HCC metastasis.
- 27 April 2016
- Published by Springer Nature in Scientific Reports
- Vol. 6 (1) , 24558
Open AccessType conversion of secretomes in a 3D TAM2 and HCC cell co-culture system and functional importance of CXCL2 in HCC
Macrophages play important roles in the tumor microenvironment, driving cancer progression and metastasis, particularly in hepatocellular carcinoma (HCC). However, few studies have assessed the exact secretome composition in HCC. In the present study, the impact of different phenotype of macrophages on HCC cells was investigated. Alternatively activated macrophages (M2) were found to significantly increase the proliferation, migration and invasion abilities of SMMC7721 cells (all P < 0.05). M2 were then co-cultured with SMMC7721 cells to reconstruct the tumor microenvironment. Conditioned medium from 3D single cultures of M2, SMMC7721 cells and their co-culture system were analyzed using quantitative proteomics via iTRAQ labeling combined with mass spectrometric analysis. Secretome analysis revealed a total of 159 differential secreted proteins in the co-culture system compared to the single culture systems, with 63 being up-regulated (>1.3-fold) and 96 down-regulated (<0.7-fold). CXCL2 was confirmed to have higher expression in the co-culture system and HCC tissues and was selected for further investigation. Functional effects data suggested that recombinant human CXCL2 significantly enhanced the migration, invasion ability of SMMC7721 cells and weakened adhesion ability. While CXCL2 neutralization and CXCR2 blockage significantly inhibited the effects of CXCL2 on SMMC7721 cells, indicating that CXCL2 may play pivotal role in HCC metastasis.
- 11 February 2016
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 26 (7) , 684-692
Insights on N-glycosylation of human haptoglobin and its association with cancers
Protein glycosylation is one of the most significant post-translation modifications and plays a critical role in various biological functions. Haptoglobin (Hp) is one of the acute-phase response proteins secreted by liver. Its glycosylation could be analyzed by many analytical techniques qualitatively and quantitatively. The glycosylation alterations of Hp are reported to be associated with different kinds of diseases. The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching. In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp. Given the importance of Hp glycosylation, its unknown and unclear biological complexity and significances, Hp glycosylation has become a major target in cancer research. Development of sensitive and specific detection of Hp glycosylation including large-scale validation may be significant steps forward to its clinical application.
- 11 February 2016
- Published by Oxford University Press (OUP) in Glycobiology
- Vol. 26 (7) , 684-692
Insights on N-glycosylation of human haptoglobin and its association with cancers
Protein glycosylation is one of the most significant post-translation modifications and plays a critical role in various biological functions. Haptoglobin (Hp) is one of the acute-phase response proteins secreted by liver. Its glycosylation could be analyzed by many analytical techniques qualitatively and quantitatively. The glycosylation alterations of Hp are reported to be associated with different kinds of diseases. The main glycosylation alterations of Hp in cancer appear to be the presence of aberrantly fucosylated and sialylated structures as well as increased branching. In this mini review, we provided a brief overview of Hp structure and biological function, discussed its glycosylation alterations in different cancers, and described the existing technologies for analyzing glycosylation site and glycan of Hp. Given the importance of Hp glycosylation, its unknown and unclear biological complexity and significances, Hp glycosylation has become a major target in cancer research. Development of sensitive and specific detection of Hp glycosylation including large-scale validation may be significant steps forward to its clinical application.